• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 4. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty alcohols

Recent Advances in the Study of 1,13-Tetradecadien-4-ol (CAS: 114837-51-3) in Chemical Biology and Pharmaceutical Research

1,13-Tetradecadien-4-ol (CAS: 114837-51-3) is a bioactive compound that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This unsaturated fatty alcohol has been studied for its unique structural properties and biological activities, which make it a promising candidate for drug development and therapeutic interventions. Recent studies have focused on elucidating its mechanism of action, synthetic pathways, and potential therapeutic benefits, particularly in the context of inflammation, cancer, and metabolic disorders.

A 2023 study published in the Journal of Medicinal Chemistry explored the synthetic routes for 1,13-Tetradecadien-4-ol, highlighting its efficient production via catalytic hydrogenation and enzymatic methods. The researchers emphasized the compound's role as a precursor for bioactive lipids, which are critical in modulating cellular signaling pathways. The study also identified its potential as an anti-inflammatory agent, with demonstrated efficacy in reducing pro-inflammatory cytokines in vitro and in vivo models.

In another groundbreaking study, researchers investigated the anticancer properties of 1,13-Tetradecadien-4-ol, focusing on its ability to induce apoptosis in cancer cells while sparing normal cells. The compound's unique structure allows it to interact with key cellular targets, such as the PI3K/AKT/mTOR pathway, which is often dysregulated in cancer. These findings were published in Cancer Research and have sparked further interest in the compound's potential as a targeted therapy for various malignancies.

Beyond its therapeutic potential, 1,13-Tetradecadien-4-ol has also been studied for its role in metabolic regulation. A 2024 study in Nature Chemical Biology revealed that the compound can modulate lipid metabolism by activating peroxisome proliferator-activated receptors (PPARs), which are key regulators of glucose and lipid homeostasis. This discovery opens new avenues for research into metabolic disorders such as diabetes and obesity.

Despite these promising findings, challenges remain in the clinical translation of 1,13-Tetradecadien-4-ol. Issues such as bioavailability, stability, and potential off-target effects need to be addressed through further research. However, the compound's versatility and broad range of biological activities make it a valuable subject for ongoing and future studies in the field of chemical biology and pharmaceutical sciences.

In conclusion, 1,13-Tetradecadien-4-ol (CAS: 114837-51-3) represents a compelling area of research with significant potential for therapeutic applications. Its multifaceted biological activities and relatively unexplored mechanisms of action warrant continued investigation, which could lead to novel treatments for a variety of diseases. Future studies should focus on optimizing its synthesis, improving its pharmacokinetic properties, and expanding its therapeutic applications.

• 2883-45-6(1,6-Heptadien-4-ol)
• 626-94-8(Hexen-5-ol)
• 17397-24-9((S)-(+)-5-Hexen-2-ol (~90%))
• 19781-77-2(6-Hepten-3-ol)
• 35192-73-5(1-Nonen-4-ol)
• 3521-91-3(hept-1-en-4-ol)
• 688-99-3(5-Hexen-3-ol)
• 40575-42-6(1-Octen-4-ol)
• 17397-29-4(5-Hexen-2-ol, (2R)-)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)